3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
14
Terminated
3
Recruiting
3
Active not recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
19
Sarcoma
4
Gynecologic
4
Gastrointestinal
4
Thoracic
3
Genitourinary
3
Endocrine
3
Breast
3
NET
2
Dermatologic
2
CNS
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Melanoma
241
Carcinoma, Non-Small-Cell Lung
56
Carcinoma, Renal Cell
40
Skin Neoplasms
39
Uveal Melanoma
31
Squamous Cell Carcinoma of Head and Neck
30
Neoplasms
30
Colorectal Neoplasms
27
Sarcoma
25
Neoplasm Metastasis
25
Carcinoma, Merkel Cell
24
Ovarian Neoplasms
23
Lung Neoplasms
22
Stomach Neoplasms
21
Carcinoma, Basal Cell
21
Breast Neoplasms
20
Head and Neck Neoplasms
18
Esophageal Neoplasms
16
Uterine Cervical Neoplasms
15
Pancreatic Neoplasms
15
Carcinoma, Hepatocellular
15
Lymphoma, T-Cell, Cutaneous
14
Urinary Bladder Neoplasms
13
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
13
Carcinoma, Transitional Cell
13
Brain Neoplasms
13
Thyroid Neoplasms
11
Small Cell Lung Carcinoma
10
Mycosis Fungoides
10
Interventions
pembrolizumab
1
entrectinib
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Salivary Gland Neoplasms
×
Dermatologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled